Skip to main content

Crohn's & Colitis
blogs, news & research

News

Takeda Receives Approval to Manufacture and Market Alofisel in Japan


Treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease.

– Alofisel (darvadstrocel) is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan
– Alofisel provides a potential cell-mediated closure option for patients with complex perianal fistulas associated with Crohn’s disease who have shown an inadequate response to at least one existing medicinal treatment

CD is a chronic inflammatory disease of the digestive system, which affects an estimated 70,700 people in Japan. People living with CD may experience complex perianal fistulas, which can cause intense pain, bleeding, swelling, infection, and anal discharge. Despite medical and surgical advancements, complex perianal fistulas in CD remain challenging for clinicians to treat.

In a survey commissioned and conducted by the European Federation of Crohn’s & Ulcerative Colitis Associations (“EFCCA”), in collaboration with Takeda, CD patients living with perianal fistulas reported a negative impact on many aspects of their quality of life, including the ability to do sports, work and employment, dating and sexual life. Patients also reported feeling more unhygienic, uncomfortable, and guilty about their condition compared to CD patients without perianal fistulas.

“We are delighted that Alofisel has been approved in Japan for the treatment of complex perianal fistulas in Crohn’s disease patients. Complex perianal fistulas are a challenging complication of Crohn’s disease, and the approval of the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy in Japan offers a potential cell-mediated closure option to patients who do not respond to conventional or biologic therapies,” said Naoyoshi Hirota, General Manager of Takeda Development Center Japan.

The approval is based on data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel:

  • Study Darvadstrocel-3002 was a Phase 3, multicenter, open-label, uncontrolled study investigating the efficacy (24 and 52 weeks) and safety (156 weeks) of Alofisel for the treatment of complex perianal fistulas in 22 Japanese adult patients with non-active/mildly active luminal CD9,10
  • ADMIRE-CD was a randomized, double-blind, controlled, Phase 3 trial investigating the efficacy and safety of Alofisel for the treatment of complex perianal fistulas in 212 adult patients with non-active/mildly active luminal CD.A significantly greater proportion of patients in the Alofisel group compared to the control group achieved the primary endpoint of combined remission at a 24 week follow-up (51.5% vs 35.6%; 97.5% CI 0.5-31.2; P =0.021), and this was maintained over 52 weeks (56.3% vs 38.6%; 95% CI 4.2-31.2; P =0.01).11 Alofisel treatment was well-tolerated over 52 weeks, with a similar safety profile in the Alofisel group compared to the control group11

Alofisel is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan. By exhibiting immunomodulatory and local anti-inflammatory effects at the site of inflammation, it offers a new treatment option with the potential of cell-mediated closure for complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease who have shown an inadequate response to at least one existing medicinal treatment.

It is a made to order therapy that must be administered within 72 hours of manufacture. Takeda has established a manufacturing and logistics system in Japan that enables delivery to medical institutions nationwide under strict temperature control.

About Alofisel
Alofisel is a suspension of allogeneic (or donor-derived) expanded adipose-derived stem cells (eASC) for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal CD. Alofisel was granted orphan drug designation by the European Commission in 2009, the U.S. Food and Drug Administration (FDA) in 2017, and the Japanese Ministry of Health, Labour and Welfare on March 13, 2019.

Alofisel received central marketing authorization approval in the European Union in March 2018 for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. In 2019, darvadstrocel received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for complex perianal fistulas in adults with CD.

Therapeutic Indications
Alofisel is approved in the European Union/European Economic Area, Israel, Switzerland and the United Kingdom for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used only after conditioning of the fistulas.

In Japan, Alofisel is indicated for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD). This product is indicated for the treatment of patients who have shown an inadequate response to at least one existing medicinal treatment.

 

Full article here.

Posted on: September 30 2021

Leave a comment

Your email address will not be published. Required fields are marked *

No comments found.

About the author


Crohns & Colitis